<DOC>
	<DOCNO>NCT01065025</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability repeat ascend oral dos 4SC-205 patient advance incurable solid tumor malignant lymphoma .</brief_summary>
	<brief_title>Open Label , Dose Escalation Trial Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Main One evaluable target lesion accord RECIST ( CTscan , MRI caliper ) , least one evaluable target lesion ( proven CT MRI ) locate lung . Progressive disease define new progressive lesion CTscan , MRI , bone scan increase PSA . Histologically cytologically document diagnosis primary metastatic solid tumor malignant lymphomas refractory prior standard therapy standard therapy exist . Entry include , limited patient prostate breast cancer refractory hormone treatment , ovarian cancer , head neck cancer , nonsmall cell lung cancer , bladder cancer , colorectal cancer , kidney cancer , malignant melanoma malignant lymphoma . Patients refuse standard therapy also eligible . ECOG Performance Status 02 . Acceptable liver , renal bone marrow function . Main Prior treatment EG5 inhibitor . Antineoplastic therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within last 2 week long period depend defined characteristic agent use ( e.g . 6 week mitomycin C nitrosourea ) . Patients must recover treatmentrelated toxicity ( except alopecia , fatigue grade 1 neurotoxicity ) prior registration . Patients history malignancy unless undergone definitive treatment 5 year prior entry study without evidence recurrent malignant disease , exclude patient basal cell carcinoma skin ; superficial carcinoma bladder ; carcinoma prostate current PSA &lt; 0.1 ng/ml ; cervical intraepithelial neoplasia . Patients history significant cardiovascular , neurological , endocrine , gastrointestinal , respiratory inflammatory illness . Patients history , treat , suspect , hepatitis B , hepatitis C HIV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>4SC-205</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>Phase I</keyword>
</DOC>